



















27. Leapman MS, Cowan JE, Simko J, et al. Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes. *Eur Urol* 2017; 71: 750–9.
28. Abdel-Rahman O. Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to subclassify stage IV? *PLoS One* 2017; 12(11): e0188450.
29. Harshman LC, Chen YH, Liu G, et al. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. *J Clin Oncol* 2018; 36(4):376-82.
30. Laurence C, Reijkeb TM, Schroder FH. Prostate Specific Antigen: A Prognostic Marker of Survival in Good Prognosis Metastatic Prostate Cancer? (EORTC 30892). *European Urology* 2003; 44: 182–9.